Portola Pharmaceuticals receives and plans to appeal negative CHMP opinion Regarding Marke
Portola announced that the CHMP of the EMA has issued a negative opinion for betrixaban for the prevention of venous thromboembolism n adult patients hospitalized for an acute medical illness with risk factors for VTE, including VTE-related death. The Company intends to appeal the opinion. March 23, 2018